S.O.L.A.R.I.S. launches to advance scalable CAR T cell manufacturing across Europe

Bergisch Gladbach, Germany, July 16, 2026 – S.O.L.A.R.I.S., a new EU-funded project by Horizon Europe, will develop and test novel approaches to CAR T cell manufacturing to improve patient access to therapies across Europe.

S.O.L.A.R.I.S. brings together 13 partners from across Europe, spanning industry, healthcare, research, and regulatory experts. Together, they will improve the efficiency, robustness, and scalability of CAR T cell manufacturing, helping to make these therapies available to more patients. While advanced therapy medicinal products (ATMPs), including CAR T cell therapies, have expanded treatment options for patients with severe diseases, their availability remains limited due to complex, labor-intensive, and costly manufacturing processes that are difficult to scale.

"CAR T therapies have shown strong clinical potential, but broader patient access depends on making manufacturing faster, more efficient, and more scalable,” says Ian Johnston, Project Coordinator at Miltenyi Biotec. “S.O.L.A.R.I.S. supports the implementation of technological innovations in both point-of-care and centralized manufacturing scenarios.”

Developing new manufacturing solutions

As the coordinator of S.O.L.A.R.I.S., Miltenyi Biotec steers the project, supports collaboration across partners, and helps ensure progress towards its goals. Building on its expertise in cell and gene therapy, including the development of the automated CliniMACS Prodigy® cell manufacturing platform, S.O.L.A.R.I.S. will develop and implement seven new modules over the next four years. These will integrate into the existing platform to enable a digitally enhanced, highly automated manufacturing workflow that complies with Good Manufacturing Practice (GMP) standards.

Testing across European sites

The new technologies will be tested and validated at six ATMP manufacturing hubs across Europe, covering clinical, industrial, and newly established production settings. This includes both centralized facilities and point‑of‑care environments, such as hospital-based manufacturing. This will allow the technologies to be evaluated across different settings, support the development of best practices, and reduce implementation risks.

Supporting implementation and sustainability

S.O.L.A.R.I.S. will also assess ways to reduce waste, improve resource efficiency, and environmental sustainability in advanced cell therapy manufacturing. In parallel, project partners will work with regulatory experts to support the future adoption of these technologies in clinical and manufacturing environments.

By combining technology development with validation in real-world settings, S.O.L.A.R.I.S. will support more efficient and scalable manufacturing of CAR T therapies, help improve patient access, and strengthen Europe’s capabilities in advanced cell therapy manufacturing.

About S.O.L.A.R.I.S.

S.O.L.A.R.I.S. (Sterile Optimized Lean Automated Robust Integrated Scalable) is a Horizon Europe Innovation Action bringing together 13 partners from across Europe. The project aims to advance CAR T cell manufacturing through innovative automation technologies, sustainability-focused process development, regulatory integration and a European validation network.

The project receives funding from the European Union under the Horizon Europe program. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.

Key facts

Full name: S.O.L.A.R.I.S. – A new dawn in next generation CAR T manufacturing
Grant agreement: 101286693
Start date: July 16, 2026
Duration: 48 months (until June 30, 2030)
Budget: EUR 7,997,648
Coordinator: Miltenyi Biotec B.V. & Co. KG, Germany
Website: www.SOLARIS-atmp.eu

About Miltenyi Biotec

Miltenyi Biotec is a global leader in innovating technologies and services for patient-specific cell and gene therapies, turning scientific discoveries into practical treatments for personalized medicine. Having pioneered a groundbreaking method of cell separation, Miltenyi Biotec continues to set industry standards today. With over 35 years of expertise, it supports customers in biomedical discoveries, translating them into clinical applications to enable access to new therapies for patients. Miltenyi Biotec focuses on providing integrated, advanced solutions to address complex challenges in the treatment of cancers, autoimmune diseases, and inherited disorders. Through its Miltenyi Bioindustry division, it provides expert guidance to therapy developers, helping them efficiently and cost-effectively navigate the path from process development to commercialization. Miltenyi Biotec is headquartered in Bergisch Gladbach and has a global team of over 5,000 employees across 24 countries.

Go to www.miltenyibiotec.com or follow Miltenyi Biotec on LinkedIn to get the latest updates.

Contact

Kim Münster
Miltenyi Biotec, Corporate Communications
corpcom@miltenyi.com

Partners

Miltenyi Biotec B.V. & Co. KG
Stichting IMEC Nederland
Interuniversitair Micro-Electronica Centrum (IMEC Be)
Autolus Limited
Charité – Universitätsmedizin Berlin
Karolinska University Hospital Region Stockholm
University Medical Center Groningen
Fundacio Privada Per A La Recerca I La Docencia Sant Joan De Deu
Hsjd Hospital Sant Joan De Deu
Icosagen Cell Factory Ou
Cell Therapy Catapult Limited
Green Elephant Biotech GmbH
2.-0 Lca Consultants Aps
future8 gGmbH